Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
出版年份 2019 全文链接
标题
Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
作者
关键词
-
出版物
DRUGS
Volume 79, Issue 7, Pages 751-766
出版商
Springer Science and Business Media LLC
发表日期
2019-04-15
DOI
10.1007/s40265-019-01114-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treating Disease at the RNA Level with Oligonucleotides
- (2019) Arthur A. Levin NEW ENGLAND JOURNAL OF MEDICINE
- Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials
- (2019) Federica Fogacci et al. PHARMACOLOGICAL RESEARCH
- Corrigendum to: “Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)” [Atherosclerosis 259 (2017 Apr) 20–25]
- (2018) Elisa Waldmann et al. ATHEROSCLEROSIS
- Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length
- (2018) Federica Fogacci et al. DIABETES OBESITY & METABOLISM
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
- (2018) Stephen Burgess et al. JAMA Cardiology
- Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
- (2018) Laurens F. Reeskamp et al. ATHEROSCLEROSIS
- Mipomersen and its use in familial hypercholesterolemia
- (2018) Johnathon Seth Parham et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects
- (2018) Renu Nandakumar et al. JOURNAL OF LIPID RESEARCH
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
- (2017) Raimund Pechlaner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
- (2017) Frederick J Raal et al. Lancet Diabetes & Endocrinology
- A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels
- (2016) Amirhossein Sahebkar et al. CURRENT MEDICINAL CHEMISTRY
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
- (2016) P. Barton Duell et al. Journal of Clinical Lipidology
- Familial hypercholesterolaemia: A global call to arms
- (2015) Antonio J. Vallejo-Vaz et al. ATHEROSCLEROSIS
- Genetics of Familial Hypercholesterolemia
- (2015) Ariel Brautbar et al. Current Atherosclerosis Reports
- Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials
- (2015) Raju Panta et al. Journal of Clinical Lipidology
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Management of patients with familial hypercholesterolaemia
- (2015) Željko Reiner Nature Reviews Cardiology
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Lomitapide and Mipomersen
- (2014) Daniel J. Rader et al. CIRCULATION
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- Liver histology during Mipomersen therapy for severe hypercholesterolemia
- (2014) Nikroo Hashemi et al. Journal of Clinical Lipidology
- Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab
- (2014) Gilles Lambert et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers
- (2014) JoAnn D. Flaim et al. Journal of the American Heart Association
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses
- (2013) W.G. Melsen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
- (2013) Frederick Raal et al. Journal of the American Heart Association
- Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
- (2012) Stanley T. Crooke et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication
- (2012) Marianne Benn et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
- (2012) Jeremy D. Furtado et al. JOURNAL OF LIPID RESEARCH
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- (2010) Fatima Akdim et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
- (2009) Tiffany Thomas et al. Current Atherosclerosis Reports
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
- (2009) Maartje E. Visser et al. JOURNAL OF LIPID RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started